Evotaz (Atazanavir/Cobicistat) for HIV

Overview
Evotaz is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection. Evotaz is a combination drug composed of Atazanavir and Cobicistat, which are also known respectively by the abbreviations ATV and COBI. Atazanavir is an antiviral medication of the protease inhibitor (PI) class. Atazanavir is believed to work by preventing HIV from replicating in cells. Cobicistat is a pharmacokinetic enhancer. Cobicistat is believed to work by preventing the body from breaking down some antiretroviral drugs, increasing their effectiveness.

How do I take it?
Prescribing information states that Evotaz is taken once daily. Evotaz comes in tablet form.

Side effects
The FDA-approved label for Evotaz lists common side effects including jaundice and nausea. Rare but serious side effects listed for Evotaz include severe skin reactions and heart problems.

For more details about this treatment, visit:

Evotaz – Bristol-Myers Squibb

Overview of HIV Treatments – AIDS.gov